Cerebrolysin
aka FPF-1070
Mechanism
Cerebrolysin is not a single peptide but a complex biologic produced by enzymatic hydrolysis of purified porcine brain tissue, containing low-molecular-weight peptides (<10 kDa) and free amino acids. Manufactured by EVER Pharma (Austria), it is registered in 50+ countries (Europe, Asia, Russia, Latin America) for ischemic stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States.
Identification
| CAS number | 12656-61-0 |
|---|---|
| Typical dose | 5–30 mL IV daily for 10–20 day courses; lower end (5–10 mL) used for cognitive applications |
| Half-life | ~2.5–6 hours (plasma); CSF half-life ~12–18 hours; therapeutic effects persist 48–96 hours |
Vendors selling Cerebrolysin
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Orbitrex Peptides | 30 mg | $80.00 | — | 95 |
| Peptide Tech | 60 mg | $74.99 | — | 94 |
| Mile High Compounds | — | $69.99 | — | 94 |
| Hydro Research Peptides | 60 mg | $0.70 | — | 91 |
| Certified Peptides | 60 mg | $110.00 | — | 62 |
| DongCheng Peptide | — | — | — | 46 |
| zztai Peptide Ltd | — | — | — | 43 |
| AMC Essentials | 60 mg | $49.99 | — | — |
| Kimera Chems | — | $56.99 | — | — |
| Oasis Labs | 60 mg | $106.00 | — | — |
| Soma Peptides | — | $395.00 | — | — |
| Southern Aminos | 60 mg | $59.25 | — | — |
Research
Cerebrolysin has a salutary effect on impaired cerebral endothelial cell (CEC) permeability. Using an in vitro endothelial permeability assay, the present study tested the hypothesis that exosomes released by Cerebrolysin-treated CECs (Cerebro-Exos) have a robust therapeutic effect on dysfunctional CECs.
source →Kynurenic acid (KYNA), a metabolite of the L-kynurenine pathway of L-tryptophan degradation, is an endogenous blocker of glutamate ionotropic excitatory amino acid (EAA) receptors and nicotinic acetylcholine receptors (nAChRs). KYNA plays a significant role in various neuropsychiatric disorders and the aging process.
source →Background One of the primary causes of morbidity and death is still acute ischemic stroke (AIS). Although mechanical thrombectomy (MT) yields better results, problems such as partial functional recovery persist.
source →Background Long-term outcomes after endovascular thrombectomy (EVT) and the role of adjunctive neuroprotection to achieve post-stroke independence remain incompletely characterized.
source →" This study aims to measure changes in language ability after adding cerebrolysin to standard treatment for non-fluent aphasia patients with post-stroke language impairment.
source →Bell's palsy, a peripheral facial nerve paresis, is the most common disorder of the facial nerve and one of the most common mononeuropathies.
source →A prospective, single-center study would be carried out in the Neurology Department of the University Hospital "Dr. José Eleuterio González" in order to analyze the effect of cerebrolysin on the blood-brain-barrier in patients with ischemic stroke with personal history of type-2 diabetes
source →The loss of smell and taste is a prominent symptom of COVID-19. Studies found that patterns of smell loss due to Covid-19 infection differ from that of other respiratory viruses being much more profound in the Covid-19 patents and did not associate with runny, congested, or blocked-up nose.
source →Traumatic Brain Injury TBI is one of the most common causes of death and recovery failure worldwide. Each element of treatment, starting from possible surgical treatment, patient monitoring and neuroprotective treatment, can be important in the overall outcome of patients' treatment.
source →This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
source →This is a randomized, placebo-controlled, single-center clinical trial investigating the effectiveness of administrating intravenous Cerebrolysin™ (EVER NEURO Pharma, Austria), a preparation of low-molecular weight neurotrophic peptides and free amino acids, in improving the functional outcome of patients suffering fro…
source →The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke.
source →